To provide a readable introduction and access point for The Patents Act, 1970 as amended up to 1 October 2025, with emphasis on its relevance to pharmaceutical innovation, patent prosecution, patent enforcement, public health safeguards and compulsory licensing in India.
Overview #
The Patents Act, 1970 is the principal Indian legislation governing the grant, ownership, working, licensing, opposition, revocation and enforcement of patents. It sets out what inventions may be patented, the procedure for filing and examination, the rights of patentees, and the statutory limits placed on monopoly rights in the public interest.
For the pharmaceutical and healthcare sectors, the Act is especially important because it regulates patent protection for drugs, formulations, processes, biotechnology-related inventions and medical technologies, while also preserving safeguards such as exclusions from patentability, compulsory licensing and government-use provisions.
Object of the legislation #
The object of the Patents Act is to encourage genuine technological innovation by granting time-limited exclusive rights, while ensuring that patents do not obstruct public welfare, access to essential goods, scientific research, or the working of inventions in India.
In the pharmaceutical context, the Act balances private investment in research and development with public health concerns, access to medicines, prevention of evergreening, and the availability of legal mechanisms for compulsory licences in appropriate cases.
Scope and relevance #
The Act applies across India and covers patent applications, specifications, priority, publication, examination, opposition, grant, rights of patentees, term of patent, patents of addition, amendment, restoration, surrender, revocation, patent office administration, compulsory licences, government use, infringement and related proceedings.
It is relevant for patent agents, lawyers, pharmaceutical companies, generic manufacturers, research institutions, start-ups, pharmacists, healthcare policy researchers and law students. It is commonly used while analysing patentability of drug inventions, freedom-to-operate issues, patent oppositions, licensing strategy, technology transfer, generic market entry and access-to-medicines questions.
Selected important provisions and themes #
- Section 3 identifies matters that are not treated as inventions for patent purposes. In pharmaceutical practice, this provision is central to assessing patentability and preventing claims that do not meet the statutory threshold.
- Section 4 excludes inventions relating to atomic energy from patentability.
- Sections 6 to 10 deal with entitlement to apply, form of application, foreign filing information, provisional and complete specifications, and contents of specifications.
- Sections 11A to 21 cover publication, request for examination, examination by the Patent Office, search for anticipation, Controller’s consideration of the examiner’s report, refusal or amendment, divisional applications and putting the application in order for grant.
- Section 25 provides for opposition to the patent, making it a key provision for pre-grant and post-grant challenge strategy.
- Sections 43 to 53 cover grant of patents, rights conferred, conditions attached to grant, co-ownership and the term of patent.
- Sections 82 to 94 deal with working of patents, compulsory licences and revocation for non-working, including Section 84 on compulsory licences and Section 92A on compulsory licence for export of patented pharmaceutical products in exceptional circumstances.
- Sections 63 to 66 deal with surrender and revocation of patents, including revocation in public interest.
How to use this Bare Act #
- Use the Bare Act text to verify the exact statutory language before advising on patentability, filing strategy, opposition or infringement.
- For pharmaceutical inventions, read the patentability provisions together with the chapters on opposition, rights of patentees, working of patents and compulsory licensing.
- When reviewing a patent application, check entitlement to apply, specification requirements, priority, publication and examination provisions before moving to substantive patentability.
- For access-to-medicines or generic-entry issues, focus on exclusions from patentability, opposition, compulsory licensing, government-use and revocation provisions.
- For current litigation or transactional work, verify whether any rules, notifications, Patent Office practice directions or later amendments affect the statutory position.
Related Bare Acts and statutes #
- Drugs and Cosmetics Act, 1940 with Rules 1945
- Biological Diversity Act, 2002
- Designs Act, 2000
- Copyright Act, 1957
- Food Safety and Standards Act, 2006
This page refers to the text of The Patents Act, 1970 as amended up to 1 October 2025. Users should verify the latest official version, subsequent amendments, applicable Patent Rules, Patent Office practice, notifications and current judicial interpretation before relying on it for filing, litigation or regulatory strategy.
